NCT05012371 2026-03-05Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell CancerM.D. Anderson Cancer CenterPhase 2 Active not recruiting90 enrolled